Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

James Squadrito

Urology Bryn Mawr, PA Medical Doctor

NPI 1336288646 CMS profile 332646

919 Conestoga Rd, Building One Suite 300, Bryn Mawr, PA 19010

Open in the dashboard

General payments

$2,245

91 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, James Squadrito of Bryn Mawr, PA is reported in the CMS Open Payments database as having received $2,245 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $37 1
2021 General $23 1
2020 General $351 12
2019 General $1,834 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Squadrito
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to James Squadrito were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year James Squadrito Urology median Middle half National median
2019 $1,834 $480 $147–$1,201 $163
2020 $351 $246 $87–$645 $114
2021 $23 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $37 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Dendreon Pharmaceuticals LLC $420 10 payments
  2. KARL STORZ Endoscopy-America $345 13 payments
  3. Janssen Biotech, Inc. $329 9 payments
  4. Ferring Pharmaceuticals Inc. $221 10 payments
  5. Astellas Pharma US Inc $183 7 payments
  6. Amgen Inc. $131 7 payments
  7. Boston Scientific Corporation $88 4 payments
  8. Pfizer Inc. $59 4 payments
  9. Endo Pharmaceuticals Inc. $58 4 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $53 3 payments
  11. Other $358 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,245 91 payments
Products named General payments · program years 2019–2023
  1. PROVENGE $420 10 payments
  2. ERLEADA $329 9 payments
  3. FIRMAGON $221 10 payments
  4. XTANDI $219 9 payments
  5. 16 FR. FLEXIBLE VIDEO CYSTOSCOPE $111 4 payments
  6. Prolia $108 6 payments
  7. XGEVA $80 4 payments
  8. GREENLIGHT HOPKINS II OPTIK 30, 4mm $78 3 payments
  9. XIAFLEX $58 4 payments
  10. Xofigo $53 3 payments
  11. Other $607 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$30,059

Medicare's payments for the services billed

Medicare patients

65

Average age 73

Services billed

86

32 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 45%
Depression 35%
Ischemic heart disease 25%
Diabetes 23%
Cancer 23%
Chronic kidney disease 20%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record